| scholarly article | Q13442814 |
| P50 | author | Yuta Shibamoto | Q61146833 |
| P2093 | author name string | Masaki Hara | |
| Yoshitaka Sekido | |||
| Shigeru Sasaki | |||
| Hiromitsu Iwata | |||
| Hiroyuki Ogino | |||
| Shingo Hashimoto | |||
| Jun-Etsu Mizoe | |||
| Yukiko Hattori | |||
| Maiko Yoshida | |||
| Koichiro Nakajima | |||
| P2860 | cites work | Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma | Q26992004 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Hepatocellular carcinoma | Q29615841 | ||
| Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review | Q35037545 | ||
| CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors | Q35843910 | ||
| Evaluation of Focal Liver Reaction after Proton Beam Therapy for Hepatocellular Carcinoma Examined Using Gd-EOB-DTPA Enhanced Hepatic Magnetic Resonance Imaging. | Q36209900 | ||
| Whole-pelvic radiotherapy with spot-scanning proton beams for uterine cervical cancer: a planning study | Q37301081 | ||
| Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma | Q37477213 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma | Q37725272 | ||
| Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. | Q37735607 | ||
| Transient therapy-related surge in serum tumor biomarkers: characterizing behavior and postulating its biologic role | Q38049648 | ||
| The Dilemma of Serum Tumor Marker (STM) Flares | Q38194501 | ||
| Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data | Q38597546 | ||
| Spot Scanning and Passive Scattering Proton Therapy: Relative Biological Effectiveness and Oxygen Enhancement Ratio in Cultured Cells | Q38777710 | ||
| Proton beam therapy in Japan: current and future status | Q38830371 | ||
| Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma | Q38980072 | ||
| Early hepatocellular carcinoma as a signaling lesion for subsequent malignancy | Q40584888 | ||
| Investigation of the freely available easy-to-use software 'EZR' for medical statistics | Q41513106 | ||
| Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ⩽5 cm: Cohort study based on serum HCC markers | Q41546356 | ||
| Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? | Q43907269 | ||
| Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer | Q44746184 | ||
| Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis | Q45086479 | ||
| Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version). | Q47567816 | ||
| The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. | Q47688245 | ||
| Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer | Q48370850 | ||
| A proton therapy system in Nagoya Proton Therapy Center. | Q51511580 | ||
| Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. | Q51541140 | ||
| Recurrence of hepatocellular carcinoma | Q79612820 | ||
| Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy - relation to prognosis and liver function | Q84105042 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin K | Q182338 |
| hepatocellular carcinoma | Q1148337 | ||
| (E)-phytonadione | Q186093 | ||
| proton therapy | Q507667 | ||
| P304 | page(s) | 3026-3034 | |
| P577 | publication date | 2019-03-01 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma | |
| P478 | volume | 17 |
| Q90427046 | Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma | cites work | P2860 |
Search more.